J&J Announce Promising Phase 3 Interim Analysis for Single-Dose COVID-19 Vaccine Candidate1/30/2021 Vaccine Candidate 72% Effective in the US and 66% Effective Overall at Preventing Moderate to Severe COVID-19, 28 Days after Vaccination
85% Effective Overall in Preventing Severe Disease and Demonstrated Complete Protection Against COVID-19 related Hospitalization and Death as of Day 28 Protection Against Severe Disease Across Geographies, Ages, and Multiple Virus Variants, including the SARS-CoV-2 Variant from the B.1.351 Lineage [1] Observed in South Africa Single-shot compatible with standard vaccine distribution channels provides important tool in pandemic setting Press release link
0 Comments
The UK has cleared the Oxford-AstraZeneca viral vectored COVID-19 vaccine for emergency use. Link from the BBC.  There is a sliver of light at the end of the tunnel as the FDA clears the use of the Pfizer/BioNTech mRNA vaccine under an emergency use authorization! This is not full approval, but the vaccine has been determined to be safe and efficacious under independent review. As the vaccine is rolled out across the nation it will continue to monitored for rare side-effects.  On Dec. 9th, 2020, Canada became the first Western nation to approve a coronoavirus vaccine following independent review of the clinical trial data. While the United Kingdom approved the same Pfizer vaccine for use a week prior there was not an independent review of the company's clinical trial data. Link to NYT article  |
AuthorJ. Kaiser, MSc
Categories |
RSS Feed
Proudly Presented by